PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy

被引：0

作者：

Yixiang Zhu

Ye Zhang

Xingsheng Hu

Mingzhao Wang

Hongyu Wang

Yutao Liu

机构：

[1] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical Oncology

[2] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Radiation Oncology

[3] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,undefined

[4] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2022年 / 148卷

关键词：

EGFR mutation or ALK rearrangement; Brain metastasis; Immune checkpoint inhibitor (ICI); Chemotherapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：3557 / 3566

页数：9

共 50 条

[41] Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients
Tudor, Roxana Aline
D'Silva, Adrijana
Tremblay, Alain
MacEachern, Paul
Morris, Don
Brenner, Darren
Kopciuk, Karen
Bebb, Dafydd Gwyn
PLOS ONE, 2017, 12 (08):
[42] A phase II study of lorlatinib in patients (pts) with ALK-positive (ALK plus ) lung cancer with brain-only progression.
Dagogo-Jack, Ibiayi
Oxnard, Geoffrey R.
Fink, Jessica
Diubaldi, Gianluca
Helms, Caitlyn
Gainor, Justin F.
Rabin, Michael S.
Heist, Rebecca Suk
Lin, Jessica Jiyeong
Ackil, Jennifer
Muzikansky, Alona
Shaw, Alice Tsang
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[43] Retrospective Analysis of Patients Treated with Radiosurgery for 4 Brain Metastases from ALK Rearranged and EGFR Mutated NSCLC
Wang, Yan
Calbat, Courtney L.
Gomez, Daniel R.
Li, Jing
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 103 (05): : E38 - E38
[44] Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
Schmid, Sabine
Gautschi, Oliver
Rothschild, Sacha
Mark, Michael
Froesch, Patrizia
Klingbiel, Dirk
Reichegger, Hermann
Jochum, Wolfram
Diebold, Joachim
Fruh, Martin
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (04) : 681 - 688
[45] EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases
Jiang, Tao
Chu, Qian
Wang, Huijuan
Zhou, Fei
Gao, Guanghui
Chen, Xiaoxia
Li, Xuefei
Zhao, Chao
Xu, Qinghua
Li, Wei
Wu, Fengying
Xiong, Anwen
Zhao, Jing
Xu, Yaping
Su, Chunxia
Ren, Shengxiang
Zhou, Caicun
Hirsch, Fred R.
INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (10) : 2605 - 2612
[46] Pre-treated Patients with ALK-positive NSCLC benefit from Zykadia® (Ceritinib) - also in Brain Metastases
不详
ONCOLOGY RESEARCH AND TREATMENT, 2015, 38 (12) : 712 - 712
[47] Treatment-free remission after discontinuation of ALK tyrosine kinase inhibitors (TKIs) in patients with ALK-positive anaplastic large cell lymphoma (ALCL)
Kim, Jinyong
Kim, Soyeon
Kim, Tae Min
Youk, Jeonghwan
Kim, Miso
Keam, Bhumsuk
Kim, Dong-Wan
Heo, Dae Seog
CANCER RESEARCH, 2023, 83 (07)
[48] Efficacy of PD-1 monoclonal antibody SHR-1210 plus apatinib in patients with advanced nonsquamous NSCLC with wild-type EGFR and ALK.
Zhou, Caicun
Gao, Guanghui
Wang, Yi Na
Zhao, Jun
Chen, Gongyan
Liu, Zhihua
Gu, Kangsheng
Huang, Meijuan
He, Jianxing
Chen, Jianhua
Ma, Zhiyong
Feng, Ji Feng
Shi, Jianhua
Wang, Quanren
Yang, Ying
Yu, Xinmin
Cheng, Ying
Yao, Yu
Ren, Shengxiang
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[49] Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain Metastases
Martinez, Pablo
Mak, Raymond H.
Oxnard, Geoffrey R.
JAMA ONCOLOGY, 2017, 3 (09) : 1274 - 1275
[50] Beyond chemotherapy for advanced disease-the role of EGFR and PD-1 inhibitors
Gu, Weijie
Zhu, Yao
Ye, Dingwei
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2017, 6 (05) : 848 - 854

← 1 2 3 4 5 →